|
Post by dreamboatcruise on May 3, 2017 9:50:17 GMT -5
Why is it so difficult for PWD to get Afrezza? Is it true that Afrezza is more expensive compared to RAA (considering PWD may use more Afrezza units to lower BG as they can (less afraid of going low))? What's the strategy that MNKD takes to change it (either improve label SOOON or lower Afrezza price??) ? One strategy is the discount card which means that for patients with insurance, the cost to them will be $15 per month, which in most situations is no more than they'd pay for any other insulin.
|
|
|
Post by orlon on May 3, 2017 9:55:35 GMT -5
I like all of these question but in particular #4.
|
|
|
Post by dreamboatcruise on May 3, 2017 9:58:56 GMT -5
1. Can you please explain the persistent silence from Mankind Management and their lack thereof to update shareholders with any type of information? 2. Will there or will there not ever be a television commercial? 3. Why hasn't Mankind sought interviews with major news and/or talk shows? #2 They indicated that the first airing on TV will be with Reveresed. We now know that the air date is sometime in July. We do know adverts are running on screens in doctors' offices now. #3 Pharma companies are very restricted in what they can do for marketing a drug. It's probably better to have it be unrelated doctors on news programs because they are not restricted regarding positive comments and not required to run down the laundry list of side effects and warnings. I'd speculate this is the reason both Mannkind and ever other Pharma doesn't have their marketing reps go on news and talk shows.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 3, 2017 10:28:29 GMT -5
You guys suck, drop the mic and leave.
|
|
|
Post by mockingjay on May 3, 2017 10:45:25 GMT -5
don't know what to ask anymore , we are done . .73 or (.146 cent) ... I want to cry man .
|
|
|
Post by esstan2001 on May 3, 2017 11:15:52 GMT -5
don't know what to ask anymore , we are done . .73 or (.146 cent) ... I want to cry man . Low of the day so far was .666... just saying R U trying to say Mannkind has been to hell and back? Or that the shareholders have made said journey... ==>
|
|
|
Post by sophie on May 3, 2017 11:23:58 GMT -5
1. With all the increased publicity from Damon Dash, news stations airing free promotion, JDRF partnership, ADA, etc. why haven't scripts increased at all? Why do you think TV ads will have a greater impact?
2. There have been several doctors singing Afrezza's praises on TV. Surely they have more than a couple diabetic patients each. Are they just not impressed with Afrezza, are there only truly a few prescribing doctors, or are most of their patients just refusing to fill?
|
|
|
Post by prosper on May 3, 2017 13:12:05 GMT -5
Rather than ask if we should target GP's I would rather ask M&M to address this in the meeting or post on line reasons for either one. I have assumed the choice made was because of funding limitations. In my opinion it would make sense to have some portion of the sales force approach some percentage of both to see which is most effective. Someone's prior post said sales people can't even get meetings with major groups because of group policies. Rather than beating our heads against the wall, have some percentage of sales force devote some percentage of time to small groups of doctors.
|
|
|
Post by dreamboatcruise on May 3, 2017 13:28:24 GMT -5
Rather than ask if we should target GP's I would rather ask M&M to address this in the meeting or post on line reasons for either one. I have assumed the choice made was because of funding limitations. In my opinion it would make sense to have some portion of the sales force approach some percentage of both to see which is most effective. Someone's prior post said sales people can't even get meetings with major groups because of group policies. Rather than beating our heads against the wall, have some percentage of sales force devote some percentage of time to small groups of doctors. Another potential reason endos are still worth pursuing is that we have seen the power of combining Dexcom with Afrezza to get really impressive results. I imagine PCPs that have been treating PWD with orals, might be willing to add Afrezza into the mix, but training staff on supporting CGM is probably a higher hurdle. I would suspect that almost all CGMs are coming out of endo offices. I would hope the strategy would be to quickly try to determine a doctor's state of open-mindedness, and spend the effort on those that willing to accept the support that is on offer (whether endo or PCP). If I were running the sales staff, to whatever extent I could through sales reps, marketing questionnaires, etc., I'd try to build up a database of doctors and the reasons they are not yet prescribing (insurance coverage not good enough, need to see long term safety studies, need to see evidence that there is clinical benefit not just convenience, etc.). Yes, no reason to beat head against wall, but knowing when to go back to doctors would be valuable.
|
|
|
Post by sweedee79 on May 3, 2017 14:06:19 GMT -5
Rather than ask if we should target GP's I would rather ask M&M to address this in the meeting or post on line reasons for either one. I have assumed the choice made was because of funding limitations. In my opinion it would make sense to have some portion of the sales force approach some percentage of both to see which is most effective. Someone's prior post said sales people can't even get meetings with major groups because of group policies. Rather than beating our heads against the wall, have some percentage of sales force devote some percentage of time to small groups of doctors. from my perspective the endos are who we should be targeting.. when my dad went to his GP and asked for Afrezza the doc wouldn't touch it .. dad persisted so she sent him to an endos office to get the script. Most GPs are even busier than the endo IMO ... have a larger caseload, spend less time with the patient and don't specialize.. When we finally got to the endos office, it wasn't even an endo who saw us but rather a nurse practitioner who specializes in diabetes. Yet, she was at least aware of Afrezza and gave my dad a script. However it was clear to me that she didn't really understand the drug since she prescribed to him the same dose as he had been on while on injectable.... and was very fearful of raising doses due to hypo ...
IMO what we have seen is a new product that changes the standard of care. Endos don't know this... They don't see the need to change to something else when what they are using is working just fine according to the current standard of care. People don't change easily..... On top of that we have had barely any dtc advertising... and we have had insurance problems... etc..
What we have been attempting to do takes a lot of cash and a new label... and time... none of which we have... Hindsight is 20/20, but perhaps there were things that needed to be done before Afrezza ever went to market... I just don't know...
|
|
|
Post by promann on May 3, 2017 14:35:26 GMT -5
Rather than ask if we should target GP's I would rather ask M&M to address this in the meeting or post on line reasons for either one. I have assumed the choice made was because of funding limitations. In my opinion it would make sense to have some portion of the sales force approach some percentage of both to see which is most effective. Someone's prior post said sales people can't even get meetings with major groups because of group policies. Rather than beating our heads against the wall, have some percentage of sales force devote some percentage of time to small groups of doctors. from my perspective the endos is who we should be targeting.. when my dad went to his GP and asked for Afrezza the doc wouldn't touch it .. dad persisted so she sent him to an endos office to get the script. Most GPs are even busier than the endo IMO ... have a larger caseload, spend less time with the patient and don't specialize.. When we finally got to the endos office, it wasn't even an endo who saw us but rather a nurse practitioner who specializes in diabetes. Yet, she was at least aware of Afrezza and gave my dad a script. However it was clear to me that she didn't really understand the drug since she prescribed to him the same dose as he had been on while on injectable.... and was very fearful of raising doses due to hypo ...
IMO what we have seen is a new product that changes the standard of care. Endos don't know this... They don't see the need to change to something else when what they are using is working just fine according to the current standard of care. People don't change easily..... On top of that we have had barely any dtc advertising... and we have had insurance problems... etc..
What we have been attempting to do takes a lot of cash and a new label... and time... none of which we have... Hindsight is 20/20, but perhaps there were things that needed to be done before Afrezza ever went to market... I just don't know...
I hear you Sweedee, Its astonishing that PWD just are not aware of the best treatment and are just relying on their doctors advice which are stuck in the same type of treatment that are hard to educate to change. Most see a negative with possible lung issues and dont see the positive advantages that Afrezza has besides not being stuck with a needle. I feel we need to go after the younger doctors or endos the ones that are just starting out and are tech savy.. These older ones are not going to change and some still dont even know how to use a computer.. There must be a way to search for fresh Endos or doctors just starting in the field of Diabetes that are willing to hear new ways to treat Diabetes and are not stuck in the old ways...
|
|
|
Post by careful2invest on May 3, 2017 17:55:03 GMT -5
Here's my question, sorry if it is too long: From the embarrassment of publicly disclosing DeSisto as the new CEO only to realize he had a non-compete, to the year-long plus partnership with Sanofi where we seemingly sat on our hands and never thought to raise capital despite knowing Sanofi and you were not on the same page, to the year-long plus since we've gotten back Afrezza and have waivered from contract sales force to in house sales force etc., it seems unfortunately clear that foresight is at a premium with MNKD. Can you provide us with guidance as to what sales numbers you intend to hit this year (and next), when you are going to hit them, and what you are going to do to fund operations until this point? In the past, I've accepted the "competitive reasons to not disclose" excuse but I am all but convinced there is no plan and it is leading by reaction rather than strategically. Petech, It's not too long at all! We have been left in the dark and when spoken to, we have been fed multiple lines of sh it! All of your points have merit! It is most unfortunate that "Foresight is (definitely) at a premium with MNKD" All along, I felt that MNKD had to have something bigger in the plan! Their repeated blunders seemed impossible to be made by a company that had so much promise! But as it turns out, blunders are what they did best! MNKD hadn't a clue!! Unless they announce an iflux of $$ support from a heavy hitter in the next week or so, we are officially FUBAR!
|
|
|
Post by nadathing on May 3, 2017 19:49:24 GMT -5
Afrezza has been approved three years and the results it's current users are experiencing are exceeding all exceptions. At the same time no safety concerns have been raised. In fact, many afrezza user's have called it life changing. Al Mann often talked about a small country which wanted to purchase $200M of afrezza. With the safety and performance results exceeding expectations it would seem this small country would be more interested now that real world results have been realized. Are they and when can we expect the deal to be closed? The current users may have success, but over 90% who try it don't. It is not the cost. People don't fill scripts they can't afford. Afrezza is a niche drug as at least one analyst predicted a long time ago. If there is a market it is juvenile T1's and we will never make to trials. No money. It's over.
|
|
|
Post by sayhey24 on May 3, 2017 20:08:42 GMT -5
Afrezza has been approved three years and the results it's current users are experiencing are exceeding all exceptions. At the same time no safety concerns have been raised. In fact, many afrezza user's have called it life changing. Al Mann often talked about a small country which wanted to purchase $200M of afrezza. With the safety and performance results exceeding expectations it would seem this small country would be more interested now that real world results have been realized. Are they and when can we expect the deal to be closed? The current users may have success, but over 90% who try it don't. It is not the cost. People don't fill scripts they can't afford. Afrezza is a niche drug as at least one analyst predicted a long time ago. If there is a market it is juvenile T1's and we will never make to trials. No money. It's over. What are you trying to say? "It is not the cost. People don't fill scripts they can't afford." Is it they do not refill because of cost and lack of insurance? If so this is easily fixed. If you are saying 90% do not see great results you are wrong if the PWD is properly dosing. afrezza is a near-natural replacement for pancreatic function. When properly dosed they will see near non-diabetic results. All afrezza is, is the exact same monomer human insulin the pancreas secretes and has the exact same onset profile as a healthy pancreas. It is also the only diabetic treatment which replaces phase one insulin release. No other insulin analog or other diabetes drug can do this. Very simply, afrezza obsoletes all current T2 medications including metformin. It also obsoletes all currently available and work-in-progress rapid acting analogs.
|
|
|
Post by dreamboatcruise on May 3, 2017 23:55:58 GMT -5
Afrezza has been approved three years and the results it's current users are experiencing are exceeding all exceptions. At the same time no safety concerns have been raised. In fact, many afrezza user's have called it life changing. Al Mann often talked about a small country which wanted to purchase $200M of afrezza. With the safety and performance results exceeding expectations it would seem this small country would be more interested now that real world results have been realized. Are they and when can we expect the deal to be closed? I would expect closing to occur on a date involving the square root of -1. That one has always seemed quite strange to me. I've never heard of a country buying some new drug with no use within the country as a huge bulk purchase. Is it a dictatorship where doctors don't actually make prescribing decisions... where some Minister of Health says from this day forth you shall only write prescriptions for Afrezza. I'd be willing to bet that was never a very real prospect. Management has had a lot of things that they've believed in that haven't happened, but I wonder if they ever seriously thought something like that would come to pass. Al was a master promoter, so I suspect that was hyping some discussion beyond realism. Heck if they had $200M to spend they could buy the entire company now (pay off debts and have operating money left over). They'd get all the inventory MNKD currently has... and owning production would save them a lot of money not needing to buy more Afrezza since they obviously plan to have a lot of people on Afrezza to go through $200M worth before it expires.
|
|